TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immutep ( (IMMP) ) has provided an announcement.
Immutep Limited announced that it will present new data from its AIPAC-003 Phase II trial at the 2025 San Antonio Breast Cancer Symposium. The trial, which involved heavily pretreated metastatic breast cancer patients, demonstrated strong objective response and disease control rates with the combination of eftilagimod alfa (efti) and paclitaxel. The study successfully met the FDA’s Project Optimus requirements, establishing 30 mg as the optimal biological dose for efti. This development is strategically important for Immutep’s ongoing and future clinical programs, including its global TACTI-004 Phase III trial in non-small cell lung cancer.
The most recent analyst rating on (IMMP) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative cash flows. While technical indicators suggest some positive momentum, the valuation remains unattractive due to a negative P/E ratio and lack of dividends. These factors collectively result in a below-average stock score.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), leveraging this expertise to create innovative treatment options and maximize shareholder value.
Average Trading Volume: 141,853
Technical Sentiment Signal: Sell
Current Market Cap: $284.2M
For an in-depth examination of IMMP stock, go to TipRanks’ Overview page.